Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer

High grade serous ovarian cancer (HGSOC) is a fatal gynecologic malignancy in the U.S. with limited treatment options. New therapeutic strategies include targeting of the cell cycle checkpoints, e.g., ATR and CHK1. We recently reported a promising clinical activity of the CHK1 inhibitor (CHK1i) prex...

Descripción completa

Detalles Bibliográficos
Autores principales: Nair, Jayakumar, Huang, Tzu-Ting, Murai, Junko, Haynes, Brittany, Steeg, Patricia S., Pommier, Yves, Lee, Jung-Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426265/
https://www.ncbi.nlm.nih.gov/pubmed/32647134
http://dx.doi.org/10.1038/s41388-020-1383-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426265/
https://www.ncbi.nlm.nih.gov/pubmed/32647134
http://dx.doi.org/10.1038/s41388-020-1383-4

Ejemplares similares